Inside Innovation

Last week, Sonoma Biotherapeutics announced it raised $265 million to expand both its Seattle and San Francisco operations. One of the many perks of having

After announcing its new location in Redmond, Washington last week, Evotec says their first order of business in the new 130,000-square-foot campus is to develop

In a partnership with Google, Seattle-based company Lumen BioScience can now use machine learning as a tool to expedite and streamline production of its plant-based

Last week, Seagen, a Washington-based biotech company, announced a deal with China-based RemeGen Co., Ltd. The deal, valued at $2.6 billion, allows Seagen to develop

Washington’s life science industry is thriving. In 2021 so far, almost 50 biotech companies have gone public across the U.S., with several headquartered in the

This week, Life Science Washington announced its president and CEO, Dr. Leslie Alexandre, will retire at the end of 2021. “Dr. Alexandre has been instrumental

Several Seattle-area vaccine scientists shifted their studies to focus on COVID-19 research in the past 18 months. This field of study continues to build on

Icosavax stocks are performing well amidst the Seattle-based companies new public offering. On its first day as a publicly traded company, Icosavax shares skyrocketed by

Just over a year after going public, Absci stocks are continuing to grow. The Vancouver, Washington based company now is valued at almost $2 billion.

Eliem Therapeutics, a Redmond, Washington based biotech company has filed for IPO. The filing follows two rounds of funding which took place earlier in 2021,

Lumen Bioscience, a Seattle-based biotech company announced it will be expanding its operations and moving to Seattle’s Wallingford neighborhood to continue manufacturing proteins found in

In a growing IPO market, AbSci, Vancouver, A Washington-based biotech company prepares for a public offering, joining additional Washington state biotech startups in the public